Daphnoretin Suppresses Dendritic Cell Maturation to Prevent Transplant Rejection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for tissue or organ transplant rejection and graft-versus-host disease (GVHD) are inadequate in effectively suppressing the immune response and preventing chronic rejection and toxicity.

Innovation Solution

Administration of daphnoretin, a naturally occurring compound, to attenuate the differentiation and maturation of dendritic cells, thereby reducing the immune response and preventing transplant rejection, which can be given to the donor or recipient before transplantation, and in combination with immunosuppressive agents.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current immunosuppressive treatments are used, then transplant rejection can be suppressed to some extent, but chronic rejection and toxicity still occur

Engineering Contradiction:

Improvetransplant rejection suppressionVSAvoidchronic rejection and toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and targets dendritic cells specifically as the critical immune mediators driving rejection. By using daphnoretin to selectively suppress DC differentiation and maturation, the treatment addresses the root cause of rejection while sparing other immune functions, thereby reducing chronic toxicity and rejection

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the immunosuppressive approach by targeting dendritic cell differentiation parameters rather than broad immune suppression. Daphnoretin modifies DC maturation parameters (surface markers, cytokine production, antigen presentation capability) to achieve rejection prevention without the toxic side effects of conventional immunosuppressants

Inventive Principle:

Principle #35Parameter changes

2Reliability

If strong immunosuppressive agents are administered, then acute rejection is reduced, but toxicity and side effects increase

Engineering Contradiction:

Improveacute rejection preventionVSAvoidtoxicity and side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses daphnoretin as an intermediary compound that indirectly suppresses the immune response by targeting dendritic cells. This intermediary approach provides effective acute rejection prevention while avoiding the direct toxicity of strong immunosuppressive agents on other bodily systems

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent converts the potential harm of immune suppression into benefit by specifically targeting dendritic cells. The selective suppression of DC function, which are key mediators of immune activation, provides protection against rejection while minimizing off-target toxic effects

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS10478419B2Use of daphnoretin in prevention of tissue or organ transplant rejection or graft-versus-host-disease

Publication Date: 2019.11.19 MACKAY MEMORIAL HOSPITAL

AI summary

Disclosed herein are methods of using daphnoretin to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host disease (GVHD). According to embodiments of the present disclosure, daphnoretin is administered to the recipient subject or to the donor organ prior to the transplantation to reduce immune response in the recipient subject against the transplanted organ, or to lower the risk of developing GVHD in the recipient subject.